Powered by

Moderna vs. the Lobbyists: Who Has the Upper Hand?

Apr 06, 2021 - Nasdaq

Moderna (MRNA) stock currently sits 30% below the yearly highs reached in early February. Jefferies analyst Michael Yee credits the pullback to various reasons, including a “risk-off tape and rotation away from growth stocks.”

However, the analyst also believes complaints from Public Citizen and other groups to the HHS, NIH and NIAID have played their part. The lobbying groups claim that as taxpayers funded Moderna’s Covid-19 vaccine mRNA-1273’s R&D to the tune of more than 2.5 bil...